By Fineline Cube 
InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize BM601, an innovative Class III metallic embolic microsphere for Trans‑Arterial Chemoembolization (TACE) in liver cancer. Under the deal, InnoBM will receive over 200 million CNY in milestone payments, plus sales commissions and revenue‑sharing from international markets.
Product Overview
- BM601 – Developed entirely by InnoBM, the device stems from original research by Prof. Zhuang Liu’s team at Soochow University and carries its own intellectual‑property rights.
- Mechanism – The microsphere delivers chemotherapy directly to the tumor vasculature while occluding blood flow, thereby enhancing drug concentration and reducing systemic exposure.
Clinical Impact
- Early Trials – In patients with unresectable primary liver cancer, BM601 demonstrated significant clinical advantages over conventional TACE, including higher objective response rates and improved progression‑free survival.
- Therapeutic Potential – The technology offers a more effective option for patients with intermediate and advanced‑stage liver cancer, addressing a critical unmet need in hepatocellular carcinoma management.
Strategic Value
- Qilu’s Role – As a leading Chinese generic‑drug manufacturer, Qilu will leverage its global distribution network to bring BM601 to international markets, creating a new revenue stream for both companies.
- Milestone Structure – The 200 million CNY milestone framework aligns incentives with product performance, encouraging rapid commercialization and further clinical development.-Fineline Info & Tech